The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals' Mimrylo (rusfertide) as a new treatment for adults ...

Add-on therapy was linked to faster immune tolerance and fewer treated bleeds in a small study of children with hemophilia A.

Updated COVID vaccines are necessary, just as flu vaccines are updated because immunity wanes with time, even among those ...

FDA approves updated 2026-2027 COVID-19 vaccine formulations targeting the XFG variant for older adults and high-risk individuals.

FDA approves Mimrylo (rusfertide), the first hepcidin mimetic for polycythemia vera. Takeda's breakthrough treatment offers ...

Karyopharm Therapeutics announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

The FDA has approved the first treatment for essential thrombocythemia in nearly 30 years, according to a PharmaEssentia ...

The FDA has approved Mimrylo (rusfertide) to treat adults with polycythemia vera (PV), a blood cancer that causes the overproduction of red blood cells. The excess cells thicken t ...

FDA approves rusfertide (Mimrylo), a first-in-class hepcidin mimetic that regulates iron to control erythrocytosis in ...

Bengaluru: The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, the health regulator said ...

If companies played fair, you wouldn't need ambulance chaser lawyers. Here are 18 times when dangers were fixed when ...

Merck surged 44% YTD, topping Amgen's 35%, and it achieved the sector's top performance through oncology and newer launches rather than a GLP-1 obesity franchise. Pfizer's 6.3% dividend yield keeps ...